Stock BOLT BOLT BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-17 EDT 		5-day change 1st Jan Change
0.7929 USD -3.90% Intraday chart for Bolt Biotherapeutics, Inc. -37.07% -29.21%
05-15 Top Midday Decliners MT
05-15 Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT
PR
Top Midday Decliners
MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%
MT
Top Premarket Decliners
MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket
MT
Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3
MT
Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy
MT
HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy
MT
Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6
MT
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
GL
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
GL
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
GL
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
GL
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu
CI
Bolt Biotherapeutics Insider Sold Shares Worth $128,993, According to a Recent SEC Filing
MT
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BOLT Stock
  4. News Bolt Biotherapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW